Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
Recruitment status was Recruiting
This study is designed to explore the use of Myfortic® in patients with steroid-refractory uveitis. The aim of the study will be to show the therapeutic effect of Myfortic® in managing uveitis patients.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study|
|Study Start Date:||January 2009|
|Estimated Study Completion Date:||December 2011|
This study is a single arm prospective evaluation in which patients with uveitis are treated with Myfortic® in a dose of 360 mg bid for six months. From day 0, Myfortic will be combined with 1 mg/kg prednisone. Prednisone will be tapered from week 1 based on the clinical findings of the ophthalmologist.
There will be no other stratification of patients. After the screening, patients will be treated with Myfortic® for 6 months. Patients will be seen at month 1, 3, and 6. Thereafter patients will be followed up at month 12. Efficacy and safety assessments will be performed at each visit.
|Contact: Hwang Yih Shiou, MD||886-3-3281200 ext firstname.lastname@example.org|
|Taoyuan County, Taiwan, 333|
|Contact: Hwang Yih Shiou, MD 886-3-3281200 ext 8666 email@example.com|
|Principal Investigator:||Hwang Yih Shiou, MD||CGMH|